Tacrolimus (TAC), a potent immunosuppressive macrolide, has been investigated for ocular diseases due to promising results in the treatment of anterior and posterior segments eye diseases. Mesoporous and functionalized silica nanoparticles show potential as TAC delivery platforms owing to their interesting characteristic as large surface area, uniform pore size distribution, high pore volume, and excellent biocompatibility. The purpose of this study was to incorporate TAC in functionalized silica nanoparticles with 3-aminopropyltriethoxysilane (MSNAPTES) and investigate the safety and biocompatibility of the systems. The MSNAPTES and MSNAPTES TAC nanoparticles were characterized. The in vitro cytotoxicity of MSNAPTES and MSNAPTES load with TAC (MSNAPTES-TAC) in retinal pigment epithelial cells (ARPE-19) was determined, chorioallantoic membrane (CAM) assay model was used to investigate the in vivo biocompatibility, and safety of intravitreal injection was evaluated using clinical examination (assessment of intraocular pressure and indirect fundus ophthalmoscopy), electroretinographic (ERG) and histologic studies in rats’ eyes. The elemental analysis (CHN), thermogravimetric (TGA), photon correlation spectroscopy and Fourier transform infrared (FTIR) analysis confirmed the presence of functionalized agent and TAC in the MSNAPTES nanoparticles. TAC loading was estimated at 7% for the MSNAPTES TAC nanoparticles. MSNAPTES and MSNAPTES TAC did not present in vitro cytotoxicity. The drug delivery systems showed good biocompatibility on CAM. No retinal abnormalities, vitreous hemorrhage, neovascularization, retinal detachment, and optic nerve atrophy were observed during the in vivo study. Follow-up ERGs showed no changes in the function of the retina cells after 15 days of intravitreal injection, and histopathologic observations support these findings. In conclusion, MSNAPTES TAC was successfully synthesized, and physicochemical analyses confirmed the presence of TAC in the nanoparticles. In vitro and in vivo studies indicated that MSNAPTES TAC was safe to intravitreal administration. Taking into account the enormous potential of MSNAPTES to carry TAC, this platform could be a promising strategy for TAC ocular drug delivery in the treatment of eye diseases.
RikkersSMHollandGNDraytonGE, et al.
Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol2003;
135: 297–302.
2.
BarotRKShitoleSCBhagatN, et al.
Therapeutic effect of 0.1% tacrolimus eye ointment in allergic ocular diseases. J Clin Diagn Res2016;
10: 10–14.
3.
MiyazakiDTominagaTKakimaru-HasegawaA, et al.
Therapeutic effects of tacrolimus ointment for refractory ocular surface. Ophthalmology2008;
115: 988–992.
4.
FengXLuYLiuZ, et al.
Microbial transformation of the anti-diabetic agent corosolic acid by Cunninghamella echinulata. J Asian Nat Prod Res 2017; 19: 645--650.
5.
ZhangRHeRQianJ, et al.
Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci2010;
51: 3575–3582.
6.
ShoughySS.Topical tacrolimus in anterior segment inflammatory disorders. Eye Vis (Lond)2017;
4: 7.
7.
KaplanBHolzchuhRSakassegawa-NavesFE, et al.
Contact lens & anterior eye treatment of Sjögren’s syndrome dry eye using 0. 03% tacrolimus eye drop: prospective double-blind randomized study. Contact Lens Anterior Eye2016;
38: 373–378.
8.
Sanz-MarcoEUdaondoPGarcía-DelpechS, et al.
Treatment of refractory dry eye associated with graft versus host disease with 0.03% tacrolimus eyedrops. J Ocul Pharmacol Ther2013;
29: 776–783.
9.
MagalhaesOAMarinhoDRKwitkoS.Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study. Br J Ophthalmol2013;
97: 1395–1398.
10.
FujitaETeramuraYShiragaT, et al.
Pharmacokinetics and tissue distribution of tacrolimus (FK506) after a single or repeated ocular instillation in rabbits.J Ocul Pharmacol Ther2008;
24: 309–319.
11.
KangJHChonJKimYI, et al.
Preparation and evaluation of tacrolimus-loaded thermosensitive solid lipid nanoparticles for improved dermal distribution. Int J Nanomed2019;
14: 5381–5396.
12.
del AmoEMRimpeläAKHeikkinenE, et al.
Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res2017;
57: 134–185.
13.
RantaVPMannermaaELummepuroK, et al.
Barrier analysis of periocular drug delivery to the posterior segment. J Control Release2010;
148: 42–48.
14.
IshikawaTHokamaHKatagiriY, et al.
Effects of intravitreal injection of tacrolimus (FK506) in experimental uveitis. Curr Eye Res2005;
30: 93–101.
15.
PleyerULutzSJuskoWJ.Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Investig Ophthalmol Vis Sci1993;
34: 2737–2742.
16.
DaiYZhouRLiuL, et al.
Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): in vitro characterization and improved corneal permeation. Int J Nanomedicine2013;
8: 1921–1933.
17.
FeiW-LChenJ-QYuanJ, et al.
Preliminary study of the effect of FK506 nanospheric-suspension eye drops on rejection of penetrating keratoplasty. J Ocul Pharmacol Ther2008;
24: 235–244.
18.
GargVJainGKNirmalJ, et al.
Topical tacrolimus nanoemulsion, a promising therapeutic approach for uveitis. Med Hypotheses2013;
81: 901–904.
19.
LiQLiZZengW, et al.
Proniosome-derived niosomes for tacrolimus topical ocular delivery: in vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection. Eur J Pharm Sci2014;
62: 115–123.
20.
ZengWLiQWanT, et al.
Hyaluronic acid-coated niosomes facilitate tacrolimus ocular delivery: Mucoadhesion, precorneal retention, aqueous humor pharmacokinetics, and transcorneal permeability. Colloids Surf B Biointerfaces2016;
141: 28–35.
21.
LiuYCNgXWTeoEPW, et al.
A biodegradable, sustained-released, tacrolimus microfilm drug delivery system for the management of allergic conjunctivitis in a mouse model. Invest Ophthalmol Vis Sci2018;
59: 675–684.
22.
SouzaMCMFialhoSLSouzaPAF, et al.
Tacrolimus-loaded PLGA implants: in vivo release and ocular toxicity. Curr Eye Res2014;
39: 99–102.
23.
PenhaFMRodriguesEBFurlaniBA, et al.
Toxicological considerations for intravitreal drugs. Expert Opin Drug Metab Toxicol2011;
7: 1021–1034.
24.
ZhuSGongLLiY, et al.
Safety assessment of nanomaterials to eyes: an important but neglected issue. Adv Sci2019;
6: 1802289.
25.
Vallet-RegíMRuiz-GonzálezLIzquierdo-BarbaI, et al.
Revisiting silica based ordered mesoporous materials: medical applications. J Mater Chem2006;
16: 26–31.
26.
Vallet-RegiMTamanoiF.Overview of studies regarding mesoporous silica nanomaterials and their biomedical application. 1st ed.
Amsterdam:
Elsevier Inc., 2018.
27.
de SousaAde SouzaKCMohallemND, et al. Multifunctional Nanocomposites Based on Mesoporous Silica: Potential Applications in Biomedicine. Advances in Diverse Industrial Applications of Nanocomposites, pp. 177–202.
28.
TangFLiLChenD, et al.
The practicality of mesoporous silica nanoparticles as drug delivery devices and progress toward this goal. Nano Today2013;
46: 1278–1288.
29.
SunRWangWWenY, et al.
Recent advance on mesoporous silica nanoparticles-based controlled release system: Intelligent switches open up new horizon. Nanomaterials (Basel)2015;
5: 2019–2053.
30.
NietoAHouHSailorMJ, et al.
Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles. Exp Eye Res2013;
116: 161–168.
31.
WangCHouHNanK, et al.
Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide. Exp Eye Res2014;
129: 74–82.
32.
WartherDXiaoYLiF, et al.
Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy. Drug Deliv2018;
25: 1537–1545.
33.
Chonga. SZhaoXSKustedjoAT, et al.
Functionalization of large-pore mesoporous silicas with organosilanes by direct synthesis. Microporous Mesoporous Mater2004;
72: 33–42.
34.
FreitasLBdOCorgosinhoLdMFariaJAQA, et al.
Multifunctional mesoporous silica nanoparticles for cancer-targeted, controlled drug delivery and imaging. Microporous Mesoporous Mater2017;
242: 271–283.
35.
Izquierdo-BarbaISousaEDoadrioJC, et al.
Influence of mesoporous structure type on the controlled delivery of drugs: release of ibuprofen from MCM-48, SBA-15 and functionalized SBA-15. J Sol-Gel Sci Technol2009;
50: 421–429.
36.
AndradeGFSoaresDCFdos SantosRG, et al.
Mesoporous silica SBA-16 nanoparticles: synthesis, physicochemical characterization, release profile, and in vitro cytocompatibility studies. Microporous Mesoporous Mater2013;
168: 102–110.
37.
Paiva MrbdLageNAGuerraMCA, et al.
Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits’ eyes. Doc Ophthalmol2019;
138: 3–19.
38.
MangirNDikiciSClaeyssensF, et al.
Using ex ovo chick chorioallantoic membrane (CAM) assay to evaluate the biocompatibility and angiogenic response to biomaterials. ACS Biomater Sci Eng2019;
5: 3190–3200.
39.
ZudaireEGambardellaLKurczC, et al.
A computational tool for quantitative analysis of vascular networks. PLoS One2011;
6: e27385.
40.
OdomJVBachMBrigellM, et al.
ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol2016;
133: 1–9.
41.
JoDHKimJHLeeTG, et al.
Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases. Nanomed Nanotechnol Nanomed2015;
11: 1603–1611.
42.
UnionIPureOFChemistryA.Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity. Pure Appl Chem1985;
57: 603–619.
43.
LimaGDSAndradeGFSilva ManD, et al.
Novel kojic acid-based functionalized silica nanoparticles for tyrosinase and ache inhibition and antimicrobial applications. Chem Eng Trans2018;
64: 175–180.
44.
AndradeGFCarvalhoJLJúniorASC, et al.
Osteogenic differentiation of adipose-derived stem cells in mesoporous SBA-16 and SBA-16 hydroxyapatite scaffolds. RSC Adv2015;
5: 54551–54562.
45.
DíazALópezTManjarrezJ, et al.
Growth of hydroxyapatite in a biocompatible mesoporous ordered silica. Acta Biomater2006;
2: 173–179.
46.
YangXZhaoNZhouQ, et al.
Facile preparation of hollow amino-functionalized organosilica microspheres by a template-free method. J Mater Chem2012;
22: 18010–18017.
47.
PatelPVPanchalSSMehtaTA.Improvement of dissolution rate of tacrolimus by solid dispersion technique. J Pharm Investig2013;
43: 45–53.
48.
YamashitaKNakateTOkimotoK, et al.
Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm2003;
267: 79–91.
49.
HouHHuffmanKRiosS, et al.
A novel approach of daunorubicin application on formation of proliferative retinopathy using a porous silicon controlled delivery system. Invest Ophthalmol Vis Sci2015;
56: 2755–2763.
50.
NietoAHouHMoonSW, et al.
Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin. Invest Ophthalmol Vis Sci2015;
56: 1070–1080.
51.
ZhaiJGuJYuanJ, et al.
Tacrolimus in the treatment of ocular diseases. BioDrugs2011;
25: 89–103.
52.
SunJGJiangQZhangXP, et al.
Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy. Int J Nanomedicine2019;
14: 1489–1501.
53.
ISO I. 10993?5: 2009 Biological evaluation of medical devices--part 5: tests for in vitro cytotoxicity. International Organization for Standardization, Geneva, 2009.
54.
KorhonenERönkköSHillebrandS, et al.
Cytotoxicity assessment of porous silicon microparticles for ocular drug delivery. Eur J Pharm Biopharm2016;
100: 1–8.
55.
ValdesTIKreutzerDMoussyF. The chick chorioallantoic membrane as a novel in vivo model for the testing of biomaterials. Journal of Biomedical Materials Research: An Official Journal of The Society for Biomaterials 2002; 62: 273--282.
56.
PereiraBGLigorio FialhoSMaria de SouzaC, et al. Evaluation of the effects of thalidomide-loaded biodegradable devices in solid Ehrlich tumor. Biomedicine & Pharmacotherapy 2013; 67: 129--132.
57.
LopesBResendeRMPaivaMRB, et al.
Sirolimus-loaded biodegradable implants induce long lasting anti-inflammatory and antiangiogenic effects. J Drug Deliv Sci Technol2018;
44: 373–379.
58.
PassosEGenaidyMMPeymanGA.Ocular toxicity of intravitreal tacrolimus. Ophthalmic Surg Lasers2002;
33: 140–144.
59.
ChengLAnglinECuninF, et al.
Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle. Br J Ophthalmol2008;
92: 705–711.
60.
ParkJHJeongHHongJ, et al.
The effect of silica nanoparticles on human corneal epithelial cells. Sci Rep2016;
6: 37762–37711.
61.
HouHNietoABelghithA, et al.
A sustained intravitreal drug delivery system with remote real time monitoring capability. Acta Biomater2015;
24: 309–321.
